Research ArticleArticle
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng and Annelies Boonen
The Journal of Rheumatology February 2021, jrheum.201088; DOI: https://doi.org/10.3899/jrheum.201088
Peter C. Taylor
This study was sponsorred by Celgene. Amgen Inc. acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. PCT acknowledges support from the National Institute for Health Research Oxford Biomedical Research Centre and from AR UK. P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands; S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA; A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. PCT has received grant/research support from Celgene. DvdH has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, and is a director of Imaging Rheumatology BV. RL has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer, and UCB Pharma, and received an honorarium from Celgene for reading films for this study. SM is a former employee of Celgene and Amgen. SC is an employee of Amgen and a former employee of Celgene. AB has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK. Email: peter.taylor@kennedy.ox.ac.uk. Accepted for publication February 2, 2021.
Désirée van der Heijde
This study was sponsorred by Celgene. Amgen Inc. acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. PCT acknowledges support from the National Institute for Health Research Oxford Biomedical Research Centre and from AR UK. P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands; S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA; A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. PCT has received grant/research support from Celgene. DvdH has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, and is a director of Imaging Rheumatology BV. RL has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer, and UCB Pharma, and received an honorarium from Celgene for reading films for this study. SM is a former employee of Celgene and Amgen. SC is an employee of Amgen and a former employee of Celgene. AB has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK. Email: peter.taylor@kennedy.ox.ac.uk. Accepted for publication February 2, 2021.
Robert Landewé
This study was sponsorred by Celgene. Amgen Inc. acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. PCT acknowledges support from the National Institute for Health Research Oxford Biomedical Research Centre and from AR UK. P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands; S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA; A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. PCT has received grant/research support from Celgene. DvdH has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, and is a director of Imaging Rheumatology BV. RL has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer, and UCB Pharma, and received an honorarium from Celgene for reading films for this study. SM is a former employee of Celgene and Amgen. SC is an employee of Amgen and a former employee of Celgene. AB has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK. Email: peter.taylor@kennedy.ox.ac.uk. Accepted for publication February 2, 2021.
Shannon McCue
This study was sponsorred by Celgene. Amgen Inc. acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. PCT acknowledges support from the National Institute for Health Research Oxford Biomedical Research Centre and from AR UK. P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands; S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA; A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. PCT has received grant/research support from Celgene. DvdH has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, and is a director of Imaging Rheumatology BV. RL has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer, and UCB Pharma, and received an honorarium from Celgene for reading films for this study. SM is a former employee of Celgene and Amgen. SC is an employee of Amgen and a former employee of Celgene. AB has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK. Email: peter.taylor@kennedy.ox.ac.uk. Accepted for publication February 2, 2021.
Sue Cheng
This study was sponsorred by Celgene. Amgen Inc. acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. PCT acknowledges support from the National Institute for Health Research Oxford Biomedical Research Centre and from AR UK. P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands; S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA; A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. PCT has received grant/research support from Celgene. DvdH has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, and is a director of Imaging Rheumatology BV. RL has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer, and UCB Pharma, and received an honorarium from Celgene for reading films for this study. SM is a former employee of Celgene and Amgen. SC is an employee of Amgen and a former employee of Celgene. AB has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK. Email: peter.taylor@kennedy.ox.ac.uk. Accepted for publication February 2, 2021.
Annelies Boonen
This study was sponsorred by Celgene. Amgen Inc. acquired the worldwide rights to Otezla (apremilast) on November 21, 2019. PCT acknowledges support from the National Institute for Health Research Oxford Biomedical Research Centre and from AR UK. P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands; S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA; A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands. PCT has received grant/research support from Celgene. DvdH has served as a consultant for AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and UCB Pharma, and is a director of Imaging Rheumatology BV. RL has served as a consultant for AbbVie, Eli Lilly, Galapagos, Gilead, Merck, Novartis, Pfizer, and UCB Pharma, and received an honorarium from Celgene for reading films for this study. SM is a former employee of Celgene and Amgen. SC is an employee of Amgen and a former employee of Celgene. AB has received grant/research support from Celgene. Address correspondence to Dr. P.C. Taylor, Norman Collisson Professor of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Windmill Road Headington, Oxford, OX3 7LD, UK. Email: peter.taylor@kennedy.ox.ac.uk. Accepted for publication February 2, 2021.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Feb 2021, jrheum.201088; DOI: 10.3899/jrheum.201088